{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T12:04:52Z","timestamp":1768133092127,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00277-025-06200-9","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:42:40Z","timestamp":1737679360000},"page":"2889-2895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors"],"prefix":"10.1007","volume":"104","author":[{"given":"Manon","family":"Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyne","family":"Croizier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9gory","family":"Lazarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Quinquenel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Tassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Bourgne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc G.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9i","family":"Tchirkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"V\u00e9ron\u00e8se","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Gui\u00e8ze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"6200_CR1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE et al (2019) Ibrutinib-Rituximab or Chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 381:432\u2013443. https:\/\/doi.org\/10.1056\/NEJMoa1817073","journal-title":"N Engl J Med"},{"key":"6200_CR2","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach JA, Ruppert AS, Guinn D et al (2017) BTK(C481S)-Mediated resistance to Ibrutinib in Chronic lymphocytic leukemia. J Clin Oncol 35:1437\u20131443. https:\/\/doi.org\/10.1200\/JCO.2016.70.2282","journal-title":"J Clin Oncol"},{"key":"6200_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1182\/blood.2019000854","volume":"134","author":"A Quinquenel","year":"2019","unstructured":"Quinquenel A, Fornecker L-M, Letestu R et al (2019) Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood 134:641\u2013644. https:\/\/doi.org\/10.1182\/blood.2019000854","journal-title":"Blood"},{"key":"6200_CR4","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446\u20135456. https:\/\/doi.org\/10.1182\/blood-2007-06-093906","journal-title":"Blood"},{"key":"6200_CR5","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","volume":"129","author":"IE Ahn","year":"2017","unstructured":"Ahn IE, Underbayev C, Albitar A et al (2017) Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129:1469\u20131479. https:\/\/doi.org\/10.1182\/blood-2016-06-719294","journal-title":"Blood"},{"key":"6200_CR6","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu T-M et al (2014) Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286\u20132294. https:\/\/doi.org\/10.1056\/NEJMoa1400029","journal-title":"N Engl J Med"},{"key":"6200_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G et al (2015) Etiology of Ibrutinib Therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1:80. https:\/\/doi.org\/10.1001\/jamaoncol.2014.218","journal-title":"JAMA Oncol"},{"key":"6200_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ijc.32502","volume":"146","author":"A G\u00e1ng\u00f3","year":"2020","unstructured":"G\u00e1ng\u00f3 A, Alp\u00e1r D, Galik B et al (2020) Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int J Cancer 146:85\u201393. https:\/\/doi.org\/10.1002\/ijc.32502","journal-title":"Int J Cancer"},{"key":"6200_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/cncr.31831","volume":"125","author":"R Kanagal-Shamanna","year":"2019","unstructured":"Kanagal-Shamanna R, Jain P, Patel KP et al (2019) Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125:559\u2013574. https:\/\/doi.org\/10.1002\/cncr.31831","journal-title":"Cancer"},{"key":"6200_CR10","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","volume":"6","author":"P Blombery","year":"2022","unstructured":"Blombery P, Thompson ER, Lew TE et al (2022) Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv 6:5589\u20135592. https:\/\/doi.org\/10.1182\/bloodadvances.2022008325","journal-title":"Blood Adv"},{"key":"6200_CR11","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/blood.2024025237","volume":"144","author":"LE Roeker","year":"2024","unstructured":"Roeker LE (2024) A fresh look at covalent BTK inhibitor resistance. Blood 144:1029\u20131031. https:\/\/doi.org\/10.1182\/blood.2024025237","journal-title":"Blood"},{"key":"6200_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood.2023023659","volume":"144","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, Jones D, Jurczak W et al (2024) Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood 144:1061\u20131068. https:\/\/doi.org\/10.1182\/blood.2023023659","journal-title":"Blood"},{"key":"6200_CR13","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1182\/blood-2023-173547","volume":"142","author":"JR Brown","year":"2023","unstructured":"Brown JR, Li J, Eichhorst BF et al (2023) Acquired mutations in patients (pts) with Relapsed\/Refractory (R\/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE Study. Blood 142:1890\u20131890. https:\/\/doi.org\/10.1182\/blood-2023-173547","journal-title":"Blood"},{"key":"6200_CR14","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/s41375-024-02267-x","volume":"38","author":"J Malcikova","year":"2024","unstructured":"Malcikova J, Pavlova S, Baliakas P et al (2024) ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia\u20142024 update. Leukemia 38:1455\u20131468. https:\/\/doi.org\/10.1038\/s41375-024-02267-x","journal-title":"Leukemia"},{"key":"6200_CR15","doi-asserted-by":"publisher","unstructured":"Brown J, Mashima K, Fernandes S et al (2024) Mutations detected in Real World Clinical sequencing during BTK inhibitor treatment in CLL. https:\/\/doi.org\/10.21203\/rs.3.rs-3837426\/v1. Res Sq rs.3.rs-3837426","DOI":"10.21203\/rs.3.rs-3837426\/v1"},{"key":"6200_CR16","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1158\/1078-0432.CCR-22-0433","volume":"28","author":"M F\u00fcrstenau","year":"2022","unstructured":"F\u00fcrstenau M, Weiss J, Giza A et al (2022) Circulating Tumor DNA\u2013Based MRD Assessment in patients with CLL treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clin Cancer Res 28:4203\u20134211. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0433","journal-title":"Clin Cancer Res"},{"key":"6200_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood.2021015014","volume":"140","author":"JF Seymour","year":"2022","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF et al (2022) Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood 140:839\u2013850. https:\/\/doi.org\/10.1182\/blood.2021015014","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06200-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06200-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06200-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:26Z","timestamp":1749105446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06200-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6200"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06200-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samples were issued from two biological collections in the University Hospitals of Clermont-Ferrand (CPP SUD-EST VI Clermont-Ferrand AU902, DC 2011\u2009\u2212\u20091135) and Bobigny (DC 2009 936), France accordingly to the declaration of Helsinki and national regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}